Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients

Clinical Chemistry

Volumn 45, Issue 2, 1999, Pages 252-256

  Anker, Gun B ^a   Refsum, Helga ^a   Ueland, Per M ^a   Johannessen, Dag C ^a   Lien, Ernst A ^a   Lønning, Per E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIESTROGEN; AROMATASE INHIBITOR; CORTISONE ACETATE; EXEMESTANE; FORMESTANE; HOMOCYSTEINE; MEGESTROL ACETATE; VITAMIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE;

EID: 0033035448     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.2.252     Document Type: Article

References (32)

1. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann intern Med 1982;96:94-101.
2. Lønning PE. Pharmacology of new aromatase inhibitors. Breast 1996;5:202-8.
3. Clarke M, Collins R, Davies C, Godwin J, Gray R, Peto R. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-67.
4. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 1992;45:118-28.
5. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
6. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:2000-11.
7. Rutquist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1995;85:1398-406.
8. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 1995;311:977-80.
9. Anker G, Lønning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995;60:365-8.
10. Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Investig 1994;24:733-6.
11. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
12. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
13. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
14. Jones AL, Powles TJ, Law M, Tidy A, Easton E, Coombes RC, et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 1992;10:1547-52.
15. Lundgren S, Helle SI, Lønning PE. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 1996;2:1515-21.
16. Kvinnsland S, Lønning PE, Dahl O. Treatment of breast carcinoma with aminoglutethimide. Acta Radiol Oncol 1984;23:421-4.
17. Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, et al. Endocrine and clinical effects of exemstane (PNV 15921), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101-8.
18. Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AMH, Gazet J-C, et al. Treatment of advanced breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 1986;46:4823-6.
19. Lundgren S. Progestins in breast cancer treatment. Acta Oncol 1992;31:709-22.
20. Rskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: Automated determination and sample stability. Clin Chem 1993;39:263-71.
21. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-33.
22. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991;51:4837-44.
23. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
24. Cauley JA, Gutai JP, Glynn NW, Paternostro-Bayles M, Cottington E, Kuller LH. Serum estrone concentrations and coronary artery disease in postmenopausal women. Arterioscler Thromb 1994;14:14-8.
25. Dallongeville J, Marecaux N, Isorez D, Zylberberg G, Fruchart J-C, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995;118:123-33.
26. Bonneterre J, Ghalim N, Nguyen M, Puchois P, Demaille A, Demanquilly C, et al. Variations in lipoproteins during aminoglutethimide therapy. Breast Cancer Res Treat 1987;10:197-200.
27. Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart incidence. Circulation 1990;82:1916-24.
28. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrøm LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997;277:1775-81.
29. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. 1998;49:31-62.
30. Murray M, Cantrill E, Farrell GC. Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide. J Pharmacol Exp Ther 1993;265:477-81.
31. Lønning PE. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. Cancer Chemother Pharmacol 1990;26:241-4.
32. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.